Goldman Sachs recently discussed with Joe Romanelli, President of Human Health International at Merck & Co Inc (NYSE:MRK), to review Gardasil’s performance and future outlook in China. Gardasil vaccine is indicated for girls and women 9 through 45 years to prevent cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers caused by Human Papillomavirus (HPV) types. Also Read: Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations. During its second-quarter earnings report, Merck revealed challenges in the broader Chinese vaccine market and operational issues with its partner Zhifei, which led to weaker-than-expected second-quarter sales and a more cautious growth outlook for the second half of 2024. Gardasil’s sales revenue from China makes up about 50% of its total Gardasil sales, with ...